PD-L1 expression is typically measured using immunohistochemistry (IHC) techniques on tumor tissue samples. The level of PD-L1 expression is often reported as a percentage of positive cells or as a score based on staining intensity and distribution. These metrics help guide treatment decisions, particularly the use of immune checkpoint inhibitors.
